Remission of Glucocorticoid-Resistant Polymyalgia Rheumatica achieved with Tocilizumab: 2 Case Reports
<p>Polymyalgia rheumatica (PMR) is an idiopathic inflammatory disease characterized by pain and stiffness around the shoulders, neck and hips. IL-6 is an important cytokine in the pathogenesis of the disease. Although glucocorticoids (GC) are the current basic treatment, approximately 50% of p...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Rheumatica Acta: Open Access - Peertechz Publications,
2017-11-20.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | peertech__10_17352_raoa_000007 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ayse Unal Enginar |e author |
| 245 | 0 | 0 | |a Remission of Glucocorticoid-Resistant Polymyalgia Rheumatica achieved with Tocilizumab: 2 Case Reports |
| 260 | |b Rheumatica Acta: Open Access - Peertechz Publications, |c 2017-11-20. | ||
| 520 | |a <p>Polymyalgia rheumatica (PMR) is an idiopathic inflammatory disease characterized by pain and stiffness around the shoulders, neck and hips. IL-6 is an important cytokine in the pathogenesis of the disease. Although glucocorticoids (GC) are the current basic treatment, approximately 50% of patients may experience relapses during treatment. There have been case reports of resistant patients treated with Tocilizumab (TCZ), but as there has been insuffi cient evidence, the 2015 EULAR-ACR did not include TCZ treatment in the PMR recommendations.Two cases of GC-resistant PMR cases where remission was obtained with TCZ treatment are presented in this paper.</p> | ||
| 540 | |a Copyright © Ayse Unal Enginar et al. | ||
| 546 | |a en | ||
| 655 | 7 | |a Case Report |2 local | |
| 856 | 4 | 1 | |u https://doi.org/10.17352/raoa.000007 |z Connect to this object online. |